<DOC>
	<DOCNO>NCT01138098</DOCNO>
	<brief_summary>This study evaluate persistence immunity hepatitis B 10 11 year vaccination Infanrix hexa™ Engerix™-B also ability mount immune response challenge dose Engerix™-B .</brief_summary>
	<brief_title>Evaluation Antibody Persistence Immune Memory Against Hepatitis B Antigen Previously Vaccinated Children</brief_title>
	<detailed_description>Subjects participate primary study 217744/031 ( NCT01457495 ) invite age 11-12 year participate follow-up study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects investigator believe parents/Legally acceptable representative ) comply requirement protocol enrol study . A male female age 1112 year time study entry ( include 11th birthday exclude 13th birthday ) . Written inform consent obtain parent Legally Acceptable Representative subject . Study procedure explain subject depend understanding , optional informed assent seek discretion investigator . Written inform assent obtain subject addition inform consent sign parent ( ) / Legally Acceptable Representative ( ) . Healthy subject establish medical history clinical examination enter study . Subjects receive three dos Infanrix hexa EngerixB primary study 217744/031 ( NCT01457495 ) . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Child care . Use investigational nonregistered product drug vaccine ) study vaccine within 30 day precede challenge dose HBV vaccine , plan use study period . Receipt hepatitis B ( contain ) vaccine vaccination primary study 217744/031 ( NCT01457495 ) . History hepatitis B disease . Planned administration/administration vaccine foreseen study protocol period start 30 day end 30 day HBV vaccine challenge dose . Administration immunoglobulins and/or blood product within three month precede challenge dose HBV vaccine plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior challenge dose HBV vaccine . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Known hypersensitivity component HBV vaccine evidence hypersensitivity previous immunisation vaccine contain hepatitis B component . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C ( 99.5°F ) oral , axillary tympanic set Subjects minor illness without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Persistence</keyword>
	<keyword>challenge dose</keyword>
	<keyword>Engerix-B</keyword>
	<keyword>immune response</keyword>
</DOC>